+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Diuretics Drugs Market by Drug Class, Indication, Route of Administration, Dosage Form, Distribution Channel - Global Forecast to 2030- Product Image
Diuretics Drugs Market by Drug Class, Indication, Route of Administration, Dosage Form, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Diuretics Drugs Market by Drug Class, Indication, Route of Administration, Dosage Form, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 183 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6084069
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Diuretics Drugs Market grew from USD 1.29 billion in 2024 to USD 1.41 billion in 2025. It is expected to continue growing at a CAGR of 8.57%, reaching USD 2.12 billion by 2030.

Setting the Stage for Diuretics Market Innovation

Diuretic drugs occupy a cornerstone position in modern therapeutic regimens, offering critical support for managing conditions ranging from hypertension and heart failure to renal disorders and glaucoma. By promoting renal excretion of sodium and water, these agents address fluid overload and intraocular pressure, delivering tangible improvements in patient outcomes. Over recent decades, incremental scientific advances have yielded diverse classes of diuretics, each with unique mechanisms of action and safety profiles. As healthcare systems worldwide grapple with aging populations, escalating chronic disease burdens, and rising costs, diuretics remain indispensable tools in the clinician’s arsenal.

This executive summary distills the latest market intelligence on global diuretics, synthesizing key trends, regulatory shifts, segmentation insights, and competitive landscapes. Our analysis offers healthcare stakeholders, pharmaceutical manufacturers, and investors a clear view of emerging opportunities and risk factors. Through a structured exploration of transformative innovations, tariff implications, regional dynamics, and strategic recommendations, this report equips decision-makers with the actionable knowledge required to navigate an evolving environment. By aligning therapeutic innovation with market demand, organizations can harness the full potential of diuretic therapies and secure sustainable growth.

Emerging Trends Reshaping the Diuretics Arena

The diuretics market is undergoing a profound metamorphosis driven by technological breakthroughs, regulatory evolution, and shifting patient expectations. Precision medicine initiatives are enabling tailored dosing regimens that optimize therapeutic efficacy while minimizing adverse events. Digital health platforms, including telemonitoring devices and mobile adherence applications, are redefining patient engagement and real-time management of fluid balance. Concurrently, the introduction of novel compounds and fixed-dose combinations targets unmet needs in resistant hypertension and complex cardiovascular disorders.

Manufacturers are also investing in sustainable manufacturing processes and green chemistry principles to reduce environmental impact, responding to both regulatory pressures and growing stakeholder demands for corporate responsibility. Biosimilar and generic entrants continue to pressure pricing structures, compelling innovators to differentiate through value-added services and outcome-based contracts. As global healthcare costs escalate, payers increasingly emphasize real-world evidence and health-economic assessments to justify reimbursement decisions. In this dynamic context, agility and strategic foresight have become essential for companies seeking to capture emerging market opportunities and drive long-term value creation.

Assessing the Repercussions of 2025 Tariff Adjustments in the US

The introduction of new United States tariffs in 2025 has reverberated across the diuretics supply chain, heightening cost pressures for active pharmaceutical ingredients predominantly sourced from overseas producers. Manufacturers facing increased import duties are reevaluating their procurement strategies, exploring alternative suppliers, and negotiating long-term agreements to mitigate volatility. The reshuffling of sourcing geographies is accelerating nearshoring initiatives, with production areas gaining prominence in regions offering favorable trade terms and logistical efficiencies.

These adjustments carry downstream implications for pricing models and profit margins, compelling both originators and generic manufacturers to reconsider margin structures and distribution agreements. Healthcare providers and pharmacy benefit managers are similarly recalibrating formulary placements to account for shifting cost structures, while patients may encounter changes in access and co-payment levels. Strategic partnerships with domestic API producers and investment in in-house manufacturing capabilities are emerging as critical responses to safeguard supply continuity and preserve competitive pricing in a tariff-impacted environment.

Unveiling Market Dynamics Through Critical Segmentation Lenses

A granular examination of market segmentation reveals nuanced growth drivers and competitive dynamics across five critical dimensions. When dissecting by drug class, Carbonic Anhydrase Inhibitors such as Acetazolamide and Dorzolamide are carving out niche positions in glaucoma management, while Loop Diuretics-represented by Bumetanide, Ethacrynic Acid, Furosemide and Torasemide-dominate heart failure protocols. Osmotic Diuretics led by Mannitol remain foundational in acute care, and Potassium-Sparing agents including Amiloride, Eplerenone, Spironolactone and Triamterene are essential for balancing electrolyte homeostasis. Thiazide Diuretics such as Bendroflumethiazide, Chlorthalidone and Hydrochlorothiazide continue to be the mainstay in hypertension therapies.

In terms of indication, the market divides among edema, glaucoma, heart failure, hypertension and renal disease, each presenting unique patient cohorts and reimbursement landscapes. Evaluation by route of administration highlights the predominance of oral formulations alongside strategic use of parenteral options for acute interventions. Dosage form analysis underscores the prevalence of tablets and capsules, complemented by injectables and liquid preparations for specialized applications. Distribution channels span hospital pharmacies, online pharmacies and retail outlets, reflecting a diversified access model that drives penetration across inpatient and outpatient settings. Together, these segmentation lenses offer a comprehensive view of where investments and targeted strategies can unlock value.

Decoding Regional Pillars Guiding Market Momentum

Regional performance in the diuretics domain is defined by distinctive market drivers, regulatory frameworks and healthcare infrastructure maturity. In the Americas, robust cardiovascular disease awareness programs and integrated healthcare delivery systems underpin high adoption of advanced diuretic therapies, with North America setting benchmarks in innovation and reimbursement models. Latin American markets are experiencing gradual expansion fueled by rising incidence of hypertension and growing access to essential medicines.

Europe, Middle East & Africa presents a heterogeneous landscape where Western Europe’s stringent regulatory standards and value-based healthcare initiatives contrast with emerging markets in Eastern Europe and the Middle East that are ramping up investments in hospital infrastructure and generic medication access. Africa’s market remains nascent, characterized by low penetration and ongoing efforts to bolster supply chain resilience and affordability. Meanwhile, Asia-Pacific commands attention through rapidly expanding patient populations, government-led chronic disease screening programs and a burgeoning generics sector in countries such as India and China. Cross-regional collaboration and harmonized regulatory pathways are increasingly critical for companies seeking to optimize their global footprint.

Profiling Industry Leaders Driving Diuretic Innovations

The competitive arena for diuretics is led by a blend of multinational pharmaceutical giants and specialized generic manufacturers. Major innovator companies have fortified their pipelines with next-generation formulations, leveraging partnerships and acquisitions to access cutting-edge technologies. Concurrently, established generics firms are pursuing volume leadership through optimized manufacturing processes and strategic alliances with local distributors. These players are differentiating through patient support programs, digital adherence solutions and outcome-oriented contracting models.

Collaborative research agreements between biopharmaceutical developers and academic institutions are driving the discovery of novel mechanisms targeting resistant hypertension and fluid overload syndromes. Meanwhile, contract development and manufacturing organizations are scaling capabilities to meet surging demand for high-purity Active Pharmaceutical Ingredients. Across the spectrum, mergers and acquisitions continue to reshape market structure, as companies seek to consolidate market share, diversify portfolios and achieve economies of scale. Insight into each leading organization’s strategic initiatives provides clarity on potential partnership opportunities and competitive threats.

Strategic Imperatives for Forward-Thinking Industry Leaders

To thrive in this evolving environment, industry leaders must prioritize agility and patient-centric innovation. Investing in precision dosing platforms and real-world evidence studies will enable differentiation in tightly contested therapeutic segments. Diversifying supply chains through dual sourcing and localized API production is essential to mitigate tariff-induced risks and ensure uninterrupted product availability. Embracing digital health technologies, including remote monitoring tools and adherence-enhancing applications, can bolster patient outcomes and strengthen value propositions for payers.

Strategic collaborations between manufacturers, contract developers and academic centers will accelerate pipeline expansion and unlock novel therapeutic pathways. Embedding sustainability into manufacturing and packaging practices not only satisfies regulatory demands but also resonates with increasingly eco-conscious stakeholders. Finally, proactive engagement with regulatory bodies to shape favorable frameworks and leverage expedited approval pathways will expedite market entry. By aligning these imperatives with robust market intelligence, organizations can secure competitive advantage and drive sustainable growth in the diuretics sector.

Methodological Framework Enhancing Market Clarity

This report synthesizes insights derived from a rigorous, multi-tiered research approach. Primary data collection included in-depth interviews with key opinion leaders, senior executives across pharmaceutical manufacturers, contract development organizations and healthcare providers. Secondary research encompassed comprehensive reviews of regulatory filings, clinical trial registries, company financial disclosures and industry publications. Quantitative data was validated through triangulation of multiple credible sources, ensuring accuracy and consistency.

Market segmentation and analysis frameworks were developed in consultation with subject matter experts and refined through cross-validation exercises. Regional insights incorporated policy reviews and reimbursement assessments to capture local nuances. Competitive profiling leveraged company-specific benchmarking, patent landscaping and merger and acquisition activity. Throughout the process, stringent quality control measures-ranging from data audits to peer reviews-safeguarded the integrity of findings. This structured methodology delivers a robust, transparent foundation for strategic decision-making.

Drawing Conclusions on Diuretics Market Trajectory

In synthesizing the multifaceted dynamics of the global diuretics market, several overarching themes emerge: the accelerating shift toward personalized and digital solutions, the critical importance of supply chain resilience amid tariff uncertainties, and the nuanced growth trajectories across key regions. By leveraging advanced segmentation insights, stakeholders can target high-value patient cohorts and optimize go-to-market strategies. The competitive landscape underscores the need for continuous innovation, strategic alliances and outcome-based partnerships to maintain differentiation in a commoditized environment.

As healthcare ecosystems continue to prioritize cost-effectiveness and real-world outcomes, diuretic therapies that demonstrate superior safety, efficacy and patient adherence will capture premium positioning. Companies that align their strategic initiatives with these evolving market imperatives-while maintaining operational agility-stand to gain sustainable competitive advantage. The insights and recommendations presented herein offer a clear roadmap for navigating upcoming challenges and capitalizing on emerging opportunities in the diuretics sector.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • Carbonic Anhydrase Inhibitors
      • Acetazolamide
      • Dorzolamide
    • Loop Diuretics
      • Bumetanide
      • Ethacrynic Acid
      • Furosemide
      • Torasemide
    • Osmotic Diuretics
      • Mannitol
    • Potassium-Sparing Diuretics
      • Amiloride
      • Eplerenone
      • Spironolactone
      • Triamterene
    • Thiazide Diuretics
      • Bendroflumethiazide
      • Chlorthalidone
      • Hydrochlorothiazide
  • Indication
    • Edema
    • Glaucoma
    • Heart Failure
    • Hypertension
    • Renal Disease
  • Route Of Administration
    • Oral
    • Parenteral
  • Dosage Form
    • Capsule
    • Injectable
    • Liquid
    • Tablet
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Viatris Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Limited
  • Dr. Reddy’s Laboratories Limited
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Cipla Limited
  • Fresenius Kabi AG

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Diuretics Drugs Market, by Drug Class
8.1. Introduction
8.2. Carbonic Anhydrase Inhibitors
8.2.1. Acetazolamide
8.2.2. Dorzolamide
8.3. Loop Diuretics
8.3.1. Bumetanide
8.3.2. Ethacrynic Acid
8.3.3. Furosemide
8.3.4. Torasemide
8.4. Osmotic Diuretics
8.4.1. Mannitol
8.5. Potassium-Sparing Diuretics
8.5.1. Amiloride
8.5.2. Eplerenone
8.5.3. Spironolactone
8.5.4. Triamterene
8.6. Thiazide Diuretics
8.6.1. Bendroflumethiazide
8.6.2. Chlorthalidone
8.6.3. Hydrochlorothiazide
9. Diuretics Drugs Market, by Indication
9.1. Introduction
9.2. Edema
9.3. Glaucoma
9.4. Heart Failure
9.5. Hypertension
9.6. Renal Disease
10. Diuretics Drugs Market, by Route of Administration
10.1. Introduction
10.2. Oral
10.3. Parenteral
11. Diuretics Drugs Market, by Dosage Form
11.1. Introduction
11.2. Capsule
11.3. Injectable
11.4. Liquid
11.5. Tablet
12. Diuretics Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Americas Diuretics Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Diuretics Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Diuretics Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Teva Pharmaceutical Industries Ltd.
16.3.2. Sandoz International GmbH
16.3.3. Viatris Inc.
16.3.4. Sun Pharmaceutical Industries Ltd.
16.3.5. Aurobindo Pharma Limited
16.3.6. Dr. Reddy’s Laboratories Limited
16.3.7. Hikma Pharmaceuticals PLC
16.3.8. Lupin Limited
16.3.9. Cipla Limited
16.3.10. Fresenius Kabi AG
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. DIURETICS DRUGS MARKET MULTI-CURRENCY
FIGURE 2. DIURETICS DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. DIURETICS DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DIURETICS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DIURETICS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DIURETICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS DIURETICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS DIURETICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES DIURETICS DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES DIURETICS DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC DIURETICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC DIURETICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. DIURETICS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. DIURETICS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DIURETICS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DIURETICS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DIURETICS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DIURETICS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ACETAZOLAMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DIURETICS DRUGS MARKET SIZE, BY DORZOLAMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DIURETICS DRUGS MARKET SIZE, BY BUMETANIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ETHACRYNIC ACID, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DIURETICS DRUGS MARKET SIZE, BY FUROSEMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DIURETICS DRUGS MARKET SIZE, BY TORASEMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DIURETICS DRUGS MARKET SIZE, BY MANNITOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DIURETICS DRUGS MARKET SIZE, BY AMILORIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DIURETICS DRUGS MARKET SIZE, BY EPLERENONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DIURETICS DRUGS MARKET SIZE, BY SPIRONOLACTONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DIURETICS DRUGS MARKET SIZE, BY TRIAMTERENE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DIURETICS DRUGS MARKET SIZE, BY BENDROFLUMETHIAZIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DIURETICS DRUGS MARKET SIZE, BY CHLORTHALIDONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DIURETICS DRUGS MARKET SIZE, BY HYDROCHLOROTHIAZIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DIURETICS DRUGS MARKET SIZE, BY EDEMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DIURETICS DRUGS MARKET SIZE, BY GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DIURETICS DRUGS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DIURETICS DRUGS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DIURETICS DRUGS MARKET SIZE, BY RENAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DIURETICS DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DIURETICS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DIURETICS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DIURETICS DRUGS MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DIURETICS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DIURETICS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DIURETICS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DIURETICS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS DIURETICS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES DIURETICS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 71. CANADA DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 72. CANADA DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 73. CANADA DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2030 (USD MILLION)
TABLE 74. CANADA DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2030 (USD MILLION)
TABLE 75. CANADA DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2030 (USD MILLION)
TABLE 76. CANADA DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2030 (USD MILLION)
TABLE 77. CANADA DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 78. CANADA DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. CANADA DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 80. CANADA DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. MEXICO DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 82. MEXICO DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 83. MEXICO DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2030 (USD MILLION)
TABLE 84. MEXICO DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2030 (USD MILLION)
TABLE 85. MEXICO DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2030 (USD MILLION)
TABLE 86. MEXICO DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2030 (USD MILLION)
TABLE 87. MEXICO DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 88. MEXICO DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. MEXICO DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 90. MEXICO DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA DIURETICS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. GERMANY DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 133. GERMANY DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 134. GERMANY DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2030 (USD MILLION)
TABLE 135. GERMANY DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2030 (USD MILLION)
TABLE 136. GERMANY DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2030 (USD MILLION)
TABLE 137. GERMANY DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2030 (USD MILLION)
TABLE 138. GERMANY DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 139. GERMANY DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. GERMANY DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 141. GERMANY DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. FRANCE DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 143. FRANCE DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 144. FRANCE DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2030 (USD MILLION)
TABLE 145. FRANCE DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2030 (USD MILLION)
TABLE 146. FRANCE DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2030 (USD MILLION)
TABLE 147. FRANCE DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2030 (USD MILLION)
TABLE 148. FRANCE DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 149. FRANCE DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. FRANCE DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 151. FRANCE DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. ITALY DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 163. ITALY DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 164. ITALY DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2030 (USD MILLION)
TABLE 165. ITALY DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2030 (USD MILLION)
TABLE 166. ITALY DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2030 (USD MILLION)
TABLE 167. ITALY DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2030 (USD MILLION)
TABLE 168. ITALY DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 169. ITALY DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. ITALY DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 171. ITALY DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. SPAIN DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 173. SPAIN DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 174. SPAIN DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2030 (USD MILLION)
TABLE 175. SPAIN DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2030 (USD MILLION)
TABLE 176. SPAIN DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2030 (USD MILLION)
TABLE 177. SPAIN DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2030 (USD MILLION)
TABLE 178. SPAIN DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 179. SPAIN DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. SPAIN DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 181. SPAIN DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 191. UNITED ARAB EMIRATES DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. SOUTH AFRICA DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 211. SOUTH AFRICA DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. DENMARK DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 213. DENMARK DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 214. DENMARK DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2030 (USD MILLION)
TABLE 215. DENMARK DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2030 (USD MILLION)
TABLE 216. DENMARK DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2030 (USD MILLION)
TABLE 217. DENMARK DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2030 (USD MILLION)
TABLE 218. DENMARK DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 219. DENMARK DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. DENMARK DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 221. DENMARK DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2030 (USD MILLION)
TABLE 228. NETHERLANDS DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 229. NETHERLANDS DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. NETHERLANDS DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 231. NETHERLANDS DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. QATAR DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 233. QATAR DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 234. QATAR DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2030 (USD MILLION)
TABLE 235. QATAR DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2030 (USD MILLION)
TABLE 236. QATAR DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2030 (USD MILLION)
TABLE 237. QATAR DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2030 (USD MILLION)
TABLE 238. QATAR DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 239. QATAR DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 240. QATAR DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 241. QATAR DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. FINLAND DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 243. FINLAND DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 244. FINLAND DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2030 (USD MILLION)
TABLE 245. FINLAND DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2030 (USD MILLION)
TABLE 246. FINLAND DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2030 (USD MILLION)
TABLE 247. FINLAND DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2030 (USD MILLION)
TABLE 248. FINLAND DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 249. FINLAND DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 250. FINLAND DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 251. FINLAND DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 260. SWEDEN DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 261. SWEDEN DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 270. NIGERIA DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 271. NIGERIA DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 272. EGYPT DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 273. EGYPT DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 274. EGYPT DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2030 (USD MILLION)
TABLE 275. EGYPT DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2030 (USD MILLION)
TABLE 276. EGYPT DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2030 (USD MILLION)
TABLE 277. EGYPT DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2030 (USD MILLION)
TABLE 278. EGYPT DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 279. EGYPT DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 280. EGYPT DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 281. EGYPT DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. TURKEY DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 283. TURKEY DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 284. TURKEY DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2030 (USD MILLION)
TABLE 285. TURKEY DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2030 (USD MILLION)
TABLE 286. TURKEY DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2030 (USD MILLION)
TABLE 287. TURKEY DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2030 (USD MILLION)
TABLE 288. TURKEY DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 289. TURKEY DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 290. TURKEY DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 291. TURKEY DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 292. ISRAEL DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 293. ISRAEL DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 294. ISRAEL DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2030 (USD MILLION)
TABLE 295. ISRAEL DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2030 (USD MILLION)
TABLE 296. ISRAEL DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2030 (USD MILLION)
TABLE 297. ISRAEL DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2030 (USD MILLION)
TABLE 298. ISRAEL DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 299. ISRAEL DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 300. ISRAEL DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 301. ISRAEL DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 302. NORWAY DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 303. NORWAY DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 304. NORWAY DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2030 (USD MILLION)
TABLE 305. NORWAY DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2030 (USD MILLION)
TABLE 306. NORWAY DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2030 (USD MILLION)
TABLE 307. NORWAY DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2030 (USD MILLION)
TABLE 308. NORWAY DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 309. NORWAY DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 310. NORWAY DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 311. NORWAY DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 312. POLAND DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 313. POLAND DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 314. POLAND DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2030 (USD MILLION)
TABLE 315. POLAND DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2030 (USD MILLION)
TABLE 316. POLAND DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2030 (USD MILLION)
TABLE 317. POLAND DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2030 (USD MILLION)
TABLE 318. POLAND DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 319. POLAND DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 320. POLAND DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 321. POLAND DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 322. SWITZERLAND DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 323. SWITZERLAND DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 324. SWITZERLAND DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2030 (USD MILLION)
TABLE 325. SWITZERLAND DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2030 (USD MILLION)
TABLE 326. SWITZERLAND DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2030 (USD MILLION)
TABLE 327. SWITZERLAND DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2030 (USD MILLION)
TABLE 328. SWITZERLAND DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 329. SWITZERLAND DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 330. SWITZERLAND DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 331. SWITZERLAND DIURETICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 332. ASIA-PACIFIC DIURETICS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 333. ASIA-PACIFIC DIURETICS DRUGS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 334. ASIA-PACIFIC DIURETICS DRUGS MARKET SIZE, BY LOOP DIURETICS, 2018-2030 (USD MILLION)
TABLE 335. ASIA-PACIFIC DIURETICS DRUGS MARKET SIZE, BY OSMOTIC DIURETICS, 2018-2030 (USD MILLION)
TABLE 336. ASIA-PACIFIC DIURETICS DRUGS MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, 2018-2030 (USD MILLION)
TABLE 337. ASIA-PACIFIC DIURETICS DRUGS MARKET SIZE, BY THIAZIDE DIURETICS, 2018-2030 (USD MILLION)
TABLE 338. ASIA-PACIFIC DIURETICS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 339. ASIA-PACIFIC DIURETICS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 340. ASIA-PACIFIC DIURETICS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 341. ASIA-PACIFIC DIURETICS DRUGS MARKET

Companies Mentioned

The companies profiled in this Diuretics Drugs market report include:
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Viatris Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Limited
  • Dr. Reddy’s Laboratories Limited
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Cipla Limited
  • Fresenius Kabi AG

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages183
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.41 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.12 Billion
Compound Annual Growth Rate8.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Diuretic Drugs - Global Strategic Business Report - Product Image

Diuretic Drugs - Global Strategic Business Report

  • Report
  • 372 Pages
  • Global
From
Diuretic Drugs Market 2024-2028 - Product Image

Diuretic Drugs Market 2024-2028

  • Report
  • 137 Pages
  • Global
From
Diuretics Market Report 2025 - Product Image

Diuretics Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Nocturia - Pipeline Insight, 2025 - Product Image

Nocturia - Pipeline Insight, 2025

  • Clinical Trials
  • 40 Pages
  • Global
From

About the Diuretic Agent Market

The Diuretic Agent market is a subset of the Urological Disorders Drugs market, which focuses on medications used to treat conditions related to the urinary system. Diuretics are used to reduce the amount of fluid in the body, and are commonly prescribed to treat high blood pressure, heart failure, and kidney disease. They work by increasing the amount of salt and water that is excreted in the urine. Diuretics can also be used to reduce swelling caused by certain medical conditions. Diuretics are available in a variety of forms, including tablets, capsules, and injectables. Commonly prescribed diuretics include furosemide, hydrochlorothiazide, and spironolactone. The Diuretic Agent market is highly competitive, with many companies offering a range of products. Some of the major players in the market include Pfizer, Merck, Novartis, Sanofi, and AstraZeneca. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.